Semaglutide Research Evidence
The Semaglutide evidence base: trials, journals, and what the data does not yet show.
Key Findings at a Glance
• Semaglutide features an engineered C18 fatty acid chain that binds to serum albumin, extending its half-life from the 2 minutes of native GLP-1 to approximately 7 days for once-weekly dosing. • The SELECT cardiovascular outcomes trial demonstrated semaglutide reduces major adverse cardiac events by 20 percent in overweight patients without diabetes, establishing cardiometabolic benefits independent of glucose control. • Semaglutide is the first GLP-1 receptor agonist available as both a weekly injection and a daily oral tablet, with the oral form requiring a specialized absorption enhancer called SNAC to survive stomach acid. • At the highest approved dose for obesity, semaglutide produces average weight loss of approximately 15 percent of body weight, rivaling the results of some bariatric surgical procedures.
Neuroprotective Research
Emerging research explores potential neuroprotective applications based on GLP-1 receptor expression in the brain and observed effects on neuroinflammation and neurodegeneration pathways. Animal studies document improved cognitive function, reduced brain inflammation, and decreased amyloid-beta accumulation in Alzheimer's disease models. Clinical trials are investigating effects on Parkinson's disease progression, with preliminary data suggesting potential slowing of motor symptom decline. Research indicates possible improvements in brain insulin signaling, blood-brain barrier function, and neurogenesis. These findings have generated significant interest in GLP-1 agonists as potential therapeutic research tools for neurodegenerative disease prevention and treatment.
Trials and reviews
- EVOKE / EVOKE+Alzheimers Dement2026
missed primary endpoint in early Alzheimer's · readout Mar 2026 · N=1840
- SELECTNEJM2023
20% MACE reduction · N=17604
- STEP-HFpEFNEJM2023
symptom + weight benefit in HF · N=529
- STEP 5Nature Medicine2022
-15.2% sustained @ 104wk · N=304
- STEP 1NEJM2021
-14.9% body weight @ 68wk · N=1961
References
- Once-Weekly Semaglutide in Adults with Overweight or Obesity · Wilding JPH, et al. · 2021
- FDA Approval Announcement for Wegovy (2021). · 2021
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. · Lincoff AM, Brown-Frandsen K, Colhoun HM et al. · 2023
- Semaglutide, a glucagon like peptide-1 receptor agonist with ... - NIH · Mahapatra MK, Karuppasamy M, Sahoo BM · 2022
- Semaglutide Mechanism of Action Review. PMC. · Ghusn W, De la Rosa A, Sacoto D, Cifuentes L, Campos A, Feris F, Hurtado MD, Acosta A · 2022
- Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. · McGuire DK, Marx N, Mulvagh SL et al. · 2025
- Semaglutide | C187H291N45O59 | CID 56843331 - PubChem - NIH
- Central Nervous System Effects of GLP-1 Agonists. Nature Medicine.
- Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial. · McGuire DK, Busui RP, Deanfield J et al. · 2023
- Semaglutide - StatPearls - NCBI Bookshelf
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM. 2021. · Wilding JP, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MT, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF · 2021
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. · Perkovic V, Tuttle KR, Rossing P et al. · 2024
- Molecular mechanisms of semaglutide and liraglutide as a ... · Tamayo-Trujillo R, Ruiz-Pozo VA, Cadena-Ullauri S, Guevara-Ramírez P, Paz-Cruz E, Zambrano-Villacres R, Simancas-Racines D, Zambrano AK · 2024